Related references
Note: Only part of the references are listed.De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly
Jeong Ho Lee et al.
NATURE GENETICS (2012)
Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape
Margrith E. Mattmann et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2011)
Disruption of the Interface between the Pleckstrin Homology (PH) and Kinase Domains of Akt Protein Is Sufficient for Hydrophobic Motif Site Phosphorylation in the Absence of mTORC2
Noel A. Warfel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome
Marjorie J. Lindhurst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo
J. P. Robinson et al.
ONCOGENE (2011)
An Activating Mutation of AKT2 and Human Hypoglycemia
K. Hussain et al.
SCIENCE (2011)
Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors
Josef R. Bencsik et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Akt inhibitors in clinical development for the treatment of cancer
Sumanta Kumar Pal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Diverse somatic mutation patterns and pathway alterations in human cancers
Zhengyan Kan et al.
NATURE (2010)
Physical Association of PDK1 with AKT1 Is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase
Zhiyong Ding et al.
PLOS ONE (2010)
Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
Wen-I Wu et al.
PLOS ONE (2010)
PTEN and the PI3-Kinase Pathway in Cancer
Nader Chalhoub et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Bijay S. Jaiswal et al.
CANCER CELL (2009)
Role of a Novel PH-Kinase Domain Interface in PKB/Akt Regulation: Structural Mechanism for Allosteric Inhibition
Veronique Calleja et al.
PLOS BIOLOGY (2009)
Molecular Mechanism of an Oncogenic Mutation That Alters Membrane Targeting: Glu17Lys Modifies the PIP Lipid Specificity of the AKT1 PH Domain
Kyle E. Landgraf et al.
BIOCHEMISTRY (2008)
A novel AKT3 mutation in melanoma tumours and cell lines
M. A. Davies et al.
BRITISH JOURNAL OF CANCER (2008)
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity
Nelson Rhodes et al.
CANCER RESEARCH (2008)
The PI3K/Akt pathway: Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors
Craig W. Lindsley et al.
CURRENT CANCER DRUG TARGETS (2008)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells
S. Horn et al.
ONCOGENE (2008)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Integrative genomic approaches identify IKBKE as a breast cancer oncogene
Jesse S. Boehm et al.
CELL (2007)
Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo
Veronique Calleja et al.
PLOS BIOLOGY (2007)
Patterns of somatic mutation in human cancer genomes
Christopher Greenman et al.
NATURE (2007)
Ba/F3 cells and their use in kinase drug discovery
Markus Warmuth et al.
CURRENT OPINION IN ONCOLOGY (2007)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
CW Lindsley et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors
SF Barnett et al.
BIOCHEMICAL JOURNAL (2005)
Structure, regulation and function of PKB/AKT - a major therapeutic target
M Hanada et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2004)
The biology and clinical relevance of the PTEN tumor suppressor pathway
I Sansal et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner
J Debnath et al.
JOURNAL OF CELL BIOLOGY (2003)
Unravelling the activation mechanisms of protein kinase B/Akt
MP Scheid et al.
FEBS LETTERS (2003)
Autoinhibition of Bcr-Abl through its SH3 domain
KM Smith et al.
MOLECULAR CELL (2003)
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
J Debnath et al.
METHODS (2003)
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
M Tartaglia et al.
NATURE GENETICS (2003)
The protein kinase B/Akt signalling pathway in human malignancy
KM Nicholson et al.
CELLULAR SIGNALLING (2002)
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
M Tartaglia et al.
NATURE GENETICS (2001)
Ten years of protein kinase B signalling: a hard Akt to follow
DP Brazil et al.
TRENDS IN BIOCHEMICAL SCIENCES (2001)
Share Paper
